What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest. Some take what we at the Fool call a "motley approach" and try a little bit of everything. Others really don't have an investment strategy at all. They just throw their money at whatever looks good at the time.
Here's another angle: Learn from successful companies. In other words, see what made a given company do well in the market and find others that exhibit similar attributes. There are plenty of companies to choose from, but let's see how this approach plays out with an example from the biotech world:�Vertex Pharmaceuticals (NASDAQ: VRTX ) . Here are three investment strategy lessons from Vertex's success.
1. Understand the market opportunity.
Even the best-run company in the world won't produce stellar returns if it operates in a sector with lackluster sales potential.�Before buying a stock, make sure you understand the market opportunity. Look at the realistic potential for sales and the strength of competitors. If all looks good, the stock can advance to your next stage of analysis.
Top 5 Insurance Stocks To Invest In 2015: Endocyte Inc.(ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company?s principal SMDC product candidate, EC145, has been evaluated in a randomized Phase II clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a Phase II single-arm clinical trial for pre-treated non-small cell lung cancer. Its preclinical development products include EC0489 and EC0225, which are in Phase I clinical trial for the treatment of solid cancer tumors; EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC0531, a tubulysin conjugate to treat solid tumors; and EC0746 and EC0565 foliate receptors for the reduction o f inflammation. The company?s products under development also comprise EC20, a proprietary companion imaging diagnostic product for the identification of folate receptor in cancer patients; EC1069 for prostate cancer therapy; and EC0652 that is in early clinical trials for use as a companion imaging diagnostic for SMDCs. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.
Advisors' Opinion:- [By Henry Kawabe]
Biopharmaceutical company Endocyte (ECYT) reported a second quarter 2013 net loss of 23 cents per share, which amounted to almost three times the loss of Zacks Consensus Estimate of 8 cents per share, and a larger loss compared to the same quarter the previous year; the stock did not experience a decline. It appears as though investors have maintained confidence in the company whose stock has more than doubled over the past year. And I believe there are good reasons for such confidence in the company, and the stock. The first reason is its pipeline of drugs led by its flagship proprietary technology novel small molecule drug conjugates (SMDCs) that actively target receptors that are over-expressed on cancer cells relative to healthy cells. And the second reason is that the SMDC technology has led to its collaboration with Merck (MRK) on a cancer treatment vintafolide (EC145) that has the potential to net Endocyte $1 billion.
- [By Roberto Pedone]
Endocyte (ECYT), a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the U.S. This stock closed up 2.2% to $6.45 a share in Thursday's trading session.
Thursday's Range: $6.14-$6.48
52-Week Range: $6.01-$33.70
Thursday's Volume: 893,000
Three-Month Average Volume: 1.91 millionFrom a technical perspective, ECYT jumped higher here right above its recent 52-week low of $6.01 with lighter-than-average volume. This move higher on Thursday is starting to push shares of ECYT within range of triggering a major breakout trade. That trade will hit if ECYT manages to clear some near-term overhead resistance levels at $6.82 to $7.30 with high volume.
Traders should now look for long-biased trades in ECYT as long as it's trending above its 52-week low of $6.01 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.91 million shares. If that breakout hits soon, then ECYT will set up to re-fill some of its previous gap-down-day zone from earlier this month that started above $17.50.
- [By Jon C. Ogg]
Endocyte Inc. (NASDAQ: ECYT) is trading like the company is being acquired. This is proof that any biotech with great cancer drug news can run, regardless of market conditions. It and Merck & Co. (NYSE: MRK) have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for conditional marketing approval of Vynfinit (or vintafolide) and companion imaging components, imaging agent Folcepri (or etarfolatide), and Neocepri (intravenous folic acid), for the treatment of adult patients with ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).
10 Best Warren Buffett Stocks To Buy Right Now: PFSweb Inc.(PFSW)
PFSweb, Inc. provides business process outsourcing and ecommerce solutions in the United States, Canada, and Europe. It offers digital marketing services comprising search engine optimization, pay-per-click, affiliate marketing, comparison shopping engines, merchandising, Web analytics, customer experience, email marketing, and social media; and ecommerce technology services, including End2End eCommerce solution for the direct-to-consumer (DTC) and business-to-business (B2B) online channels. The company also provides order management services consisting of order management interfaces, collaboration technologies, and information management services; customer care services, including customer relationship management, customer order assistance, quality monitoring, and interactive voice response; and logistics and fulfillment services comprising distribution facilities and infrastructure, facility operations and management, kitting and assembly, and product management and insp ection. In addition, it offers financial management services consisting of billing, credit, collection, and cash application services for B2B clients, as well as fraud review, chargeback management, and processing and settlement credit card services for DTC clients; and professional consulting services in the areas of interactive marketing ecommerce, supply chain management, distribution and fulfillment, technology interfacing, logistics, and customer support. Further, the company provides seller services financial models, including enablement financial, agent or flash financial, and retail financial models. It serves fashion apparel and accessories, fragrance and beauty products, consumer packaged goods, home furnishings and housewares, consumer electronics, office technology and network connectivity products, and aviation spare parts industries. The company was founded in 1999 and is headquartered in Allen, Texas.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Technology stocks gained Thursday, with Infinera (NASDAQ: INFN) leading advancers. Meanwhile, gainers in the sector included LiveDeal (NASDAQ: LIVE), with shares up 5.5 percent, and PFSweb (NASDAQ: PFSW), with shares up 5.4 percent.
10 Best Warren Buffett Stocks To Buy Right Now: Societe Generale (GLE)
Societe Generale SA is a financial services company. The Company offers advisory and other services to individual customers, companies and institutions. The Company operates in five divisions: French Networks, International Retail Banking, Corporate and Investment Banking, Specialised Financial Services and Insurance, and Private Banking, Global Investment Management and Services. It operates Retail Banking in France under the Societe Generale, Credit du Nord and Boursorama brands. Its International Retail Banking is present in Central and Eastern Europe, Russia, the Mediterranean Basin, Sub-Saharan Africa, Asia and in the French Overseas territories. Private Banking, Global Investment Management and Services consist of four activities: Private Banking, Asset Management, Societe Generale Securities Services and Brokers. Advisors' Opinion:- [By Namitha Jagadeesh]
BNP Paribas SA (BNP), Societe Generale SA (GLE) and Credit Agricole SA (ACA), France�� largest banks by market value, reported second-quarter profit that exceeded analysts��estimates. Paris-based Societe Generale, which said income more than doubled from a year earlier, trades at 10.8 times projected earnings, 64 percent below its 2009 high. Credit Agricole trades at 8.6 times projected profit and BNP Paribas at 10.7 times, according to data compiled by Bloomberg.
- [By Sarah Jones]
HSBC, Europe�� biggest bank, Societe Generale SA (GLE), France�� second-largest lender, and Germany�� Commerzbank AG each climbed at least 2.6 percent after posting results. Allianz gained 3.6 percent after Europe�� largest insurer reported a jump in profit. Alstom SA (ALO) sank 12 percent after the power-equipment maker cut its profit forecast.
- [By Ruth David]
Block sales in western Europe reached $31.8 billion in the three months through September as Groupama SA sold shares in Societe Generale (GLE) SA and Sweden exited a stake in Nordea Bank (NDA) AB, data compiled by Bloomberg show. At the same time, investors poured about $22.2 billion into the region�� stock funds in the 15 weeks through Oct. 9, according to data from research firm EPFR Global Inc.
- [By Namitha Jagadeesh]
Societe Generale SA (GLE), France�� second-largest bank, advanced 1.4 percent to 31.03 euros as Goldman Sachs Group Inc. analysts recommended investors buy the shares, citing the firm�� improved funding levels.
10 Best Warren Buffett Stocks To Buy Right Now: Vista Gold Corp (VGZ)
Vista Gold Corp. (Vista), incorporated on November 28, 1983, is engaged in the evaluation, acquisition, exploration and advancement of gold exploration and potential development projects. The Company's holdings include the Mt. Todd gold project in Australia; the Guadalupe de los Reyes gold/silver project in Mexico; the Concordia gold project in Mexico; the Awak Mas gold project in Indonesia; the Long Valley gold project in California, and mining claims in Utah. On April 6, 2011, the Company announced the completion of the combination involving Midas Gold, Inc., Vista's wholly owned subsidiary, Vista Gold U.S. Inc. and its wholly owned subsidiary, Idaho Gold Resources, LLC., whereby each party contributed their respective gold assets in the Yellow Pine-Stibnite District in Idaho to a new Canadian private company named Midas Gold Corp. (Midas Gold). In October 2013, the Company announced that it has sold the Los Cardones gold project in Baja California Sur, Mexico, to the Invecture Group (Invecture) and RPG Structured Finance S.a r.l.
Mt. Todd Gold Project
The Company holds the Mt. Todd gold project through its wholly owned subsidiary, Vista Gold Australia Pty. Ltd. The project is located 56 kilometers by road northwest of Katherine, Northern Territory, Australia, and approximately 250 kilometers south of Darwin. On September 6, 2011, the Company announced the results of its mineral resource estimate for the Batman deposit at the Company�� Mt. Todd gold project in Northern Territory, Australia.
Guadalupe de los Reyes Gold/Silver Project
The Company�� Guadalupe de los Reyes project is located in the State of Sinaloa, in western Mexico, approximately halfway between the cities of Mazatlan and Culiacan. The property is held through 37 federal mining concessions totaling about 6,310.9 hectares. During the year ended December 31, 2011, the Company received the initial results of its Phase I surface sampling program completed at its Guadalupe de los Reye! s gold/silver project in Sinaloa, Mexico. In June 2011, it initiated the first phase of a two-phase exploration program. The initial results from Phase I confirmed the surface continuity of gold/silver bearing veins over a combined strike length of 14 kilometers. During October 2011, the Company received the permits for its planned drilling program at the Guadalupe de los Reyes gold/silver project, and drilling on a 12-hole core program had started.
Concordia Gold Project
The Concordia gold project is located 55 kilometers southeast of the city of La Paz, in the Mexican state of Baja California Sur. The project area covers over 3,710 hectares and is consists of 15 mining concessions. Vista holds the Concordia gold project through its wholly owned, Mexican subsidiary, Desarrollos Zapal, S.A. de C.V. (DZ Mexico). On February 7, 2012, the Company announced that the Company had entered into an Earn-in Right Agreement (the Earn-in Right Agreement) with Mexico-based Invecture Group, S.A. de C.V. (Invecture) with respect to Vista's Concordia gold project in Baja California Sur, Mexico.
Awak Mas Gold Project
The the Awak Mas gold project is held through its indirect wholly owned subsidiary, PT Masmindo Dwi. The Awak Mas property is situated on the southern side of the Central Sulawesi Metamorphic Belt within a 50-kilometer-long, north-northeast trending fault-bounded block of basement metamorphic rocks and younger sediments. On June 13, 2011, the Company�� wholly owned subsidiary, Vista Gold (Barbados) Corp. (Vista Barbados) entered into an additional option agreement (Additional Option Agreement) with Pan Asia Resources Corp. (Pan Asia). The Additional Option Agreement provides Pan Asia with the opportunity to earn an additional 20% interest in its Awak Mas gold project in Indonesia after it has earned a 60% interest in the project pursuant to the joint venture agreement between Vista Barbados and Pan Asia that was executed in December 2009. In September 20! 11, the A! dditional Option Agreement and JV Agreement were assigned from Pan Asia to Awak Mas Holdings Pty.
Long Valley Gold Project
The Long Valley gold project is located in the Inyo National Forest, about 7 miles east of the town of Mammoth Lakes, in Mono County, California. The property consists of 95 contiguous, unpatented mining claims that cover an area of approximately 1,963 acres. The Long Valley gold project is held through its indirect wholly owned subsidiary Vista Gold California LLC.
Advisors' Opinion:- [By Bryan Murphy]
A couple of days ago when gold and the SPDR Gold Trust ETF (NYSEARCA:GLD) were getting back into a bullish groove, I advocated Randgold Resources Ltd. ADR (NASDAQ:GOLD) as the better way to play gold's rebound. GOLD had fought its way back above a key ceiling, and was poised to take off... much more so than GLD was. To tell you the truth though, Randgold Resources Ltd. wasn't actually my first choice. The gold mining name I wanted to suggest was a little smaller - Vista Gold Corp. (NYSEMKT:VGZ). In the meantime, VGZ has forged out enough of the bullish progress I saw brewing then to merit a mention now.
10 Best Warren Buffett Stocks To Buy Right Now: Nuveen Floating Rate Income Fund (JFR)
Nuveen Floating Rate Income Fund is a closed-end management investment company. The Fund invests primarily in senior loans whose interest rates float or adjust periodically based on a benchmark interest rate index. Under normal market circumstances, the Fund will invest at least 80% of its managed assets in adjustable rate secured senior loans and adjustable rate unsecured senior loans, which unsecured senior loans will be, at the time of investment, investment grade quality. In addition, at least 65% of the Funds assets will be invested in senior loans that are secured by claims on specific collateral. Nuveen Asset Management is the advisor of the Fund. The sectors covered by the portfolio include media, hotels, restaurants and leisure, healthcare providers and service, chemicals, United States of America, containers/packaging and other.
Advisors' Opinion:- [By John Dowdee]
The following 10 funds satisfied all of these conditions:
BlackRock Float Rate Strategies (FRA). This CEF sells at a discount of 3%, which is low compared to an average premium of 2% over the past year. The distribution has been managed at 6.1% and a small amount (less than 10%) has been return of capital (ROC). However, this has not negatively affected net asset value (NAV) so has not been destructive. The fund holds 447 securities, with 90% in floating rate loans. FRA utilizes 27% leverage and has an expense ratio of 1.7%, including interest payments. Eaton Vance Floating Rate (EFR). This CEF sells at a 1% premium, which is low compared to an average premium of 5% over the past year. The distribution is 6.2%, none of which was ROC. The fund holds 800 securities, with 90% in floating rate loans. About 85% of the securities are from U.S. companies. EFR utilizes 35% leverage and has an expense ratio of 1.8% including interest payments. ING Prime Rate Trust (PPR). This CEF sells for a premium of 2%, which is below the average premium of 5%. It has a distribution of 6.8%, none of which was ROC. The fund has 350 holdings, virtually all in senior loans and from US companies. PPR utilizes 29% leverage and has a high expense ratio of 2.1%, including interest payments. Invesco VK Dynamic Credit Opportunities (VTA). This CEF sells for a discount of 5%, which is below the average discount of 1%. It has a distribution of 7.1%, none of which was ROC. The fund has 495 holdings, with 76% in floating rate loans. About 25% of the loans are from non-US companies. VTA utilizes a relatively low 20% leverage but still has a high expense ratio of 2.1%, including interest payments. Invesco VK Senior Income (VVR). This CEF sells for a discount of 1%, which is below the average premium of 3%. It has a distribution of 7.1%, none of which was ROC. The fund has over 500 holdings, with 89% in floating rate loans. Almost all (95%) securities are from US companies. VVR ut
10 Best Warren Buffett Stocks To Buy Right Now: Incyte Corporation(INCY)
Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Advisors' Opinion:- [By Maxx Chatsko]
Incite growth into your portfolio
Investors looking for the next high-growth biotech company should certainly spend time researching Incyte (NASDAQ: INCY ) . The company sports a handful of the most promising JAK inhibitors, which are garnering high level interest throughout the pharmaceutical industry. The molecules have big potential in treating various cancers and inflammatory diseases such as rheumatoid arthritis and psoriasis.
10 Best Warren Buffett Stocks To Buy Right Now: STR Holdings Inc(STRI)
STR Holdings, Inc., together with its subsidiaries, designs, develops, manufactures, and sells encapsulants for the solar industry worldwide. Its encapsulants protect the embedded semiconductor circuits of solar panels. The company sells its products to crystalline silicon and thin-film solar module manufacturers. STR Holdings, Inc. was founded in 1944 and is headquartered in Enfield, Connecticut.
Advisors' Opinion:- [By John Udovich]
Solar stocks have not exactly given buy and hold investors a smooth ride, but small cap�GT Advanced Technologies Inc (NASDAQ: GTAT) could be an interesting materials play on the solar sector���meaning its worth taking a closer look at the stock along with potential peers like Ascent Solar Technologies, Inc (NASDAQ: ASTI) and STR Holdings, Inc (NYSE: STRI) plus solar ETF Guggenheim Solar ETF (NYSEARCA: TAN). I should mention that just last week, we added GT Advanced Technologies to our�SmallCap Network Elite Opportunity (SCN EO) portfolio for both�fundamentals and technical reasons and we are already up almost 9%.
No comments:
Post a Comment